Inactive Instrument

Press Releases Hansa Biopharma AB Nasdaq Stockholm

Equities

SE0002148817

Real-time Estimate Cboe Europe Other stock markets 07:41:03 14/05/2024 pm IST			5-day change	1st Jan Change
36.9 ^SEK	-77.40%		-5.78%	-38.73%

18/04	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
18/04	Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Correction, Hansa Biopharma, increase in number of shares and votes	06/05	AQ
Correction: Hansa Biopharma: increase in number of shares and votes	03/05	PU
Hansa Biopharma: increase in number of shares and votes	03/05	AQ
Hansa Biopharma Q1 - Improved European launch support	19/04	AQ
Hansa Biopharma interim report January-March 2024	18/04	AQ
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	12/04	AQ
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	02/04	AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	21/03	AQ
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	22/02	AQ
Hansa Biopharma - Improved sales prospects	05/02	AQ
Hansa Biopharma Year-end report January-December 2023	02/02	AQ
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	06/01	AQ
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	15/12	AQ
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	15/12	AQ
Hansa Biopharma Nomination Committee formed	13/12	AQ
Hansa Biopharma - Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 Trial in Guillain-Barre Syndrome	08/12	AQ
Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)	07/12	AQ
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables	05/12	AQ
Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota	27/11	AQ
Hansa Biopharma Q3 update - Slow progress ahead of 2024	27/23/27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Hansa Biopharma AB Nasdaq Stockholm

Equities

SE0002148817

Press Releases

Filters